Major Depressive Disorder
Showing NaN - NaN of 86
MDD Trial in United States (SAGE-217, Placebo)
Migraine, MDD Trial in Worldwide (Fremanezumab, Placebo)
Completed
- Migraine
- Major Depressive Disorder
- Fremanezumab
- Placebo
-
Little Rock, Arkansas
- +63 more
Dec 7, 2022
MDD, Treatment Resistant Depression, Depression Trial in United States (AXS-05)
Completed
- Major Depressive Disorder
- +2 more
- AXS-05 (dextromethorphan and bupropion) oral tablets
-
Phoenix, Arizona
- +50 more
Sep 16, 2022
MDD Trial in Australia, United States (10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114)
Completed
- Major Depressive Disorder
- 10 mg PRAX-114
- +4 more
-
Lafayette, California
- +23 more
Aug 18, 2022
Treatment Resistant Depression, MDD Trial in United States (AXS-05, Placebo)
Completed
- Treatment Resistant Depression
- Major Depressive Disorder
- AXS-05
- Placebo
-
Little Rock, Arkansas
- +19 more
Jul 8, 2022
Anhedonia, MDD Trial in Puerto Rico, United States (Placebo, NBI-1065846)
Recruiting
- Anhedonia
- Major Depressive Disorder
- Placebo
- NBI-1065846
-
Birmingham, Alabama
- +11 more
Jun 27, 2022
Treatment Resistant Depression, MDD Trial in United States (AXS-05 (dextromethorphan-bupropion))
Completed
- Treatment Resistant Depression
- Major Depressive Disorder
- AXS-05 (dextromethorphan-bupropion)
-
Little Rock, Arkansas
- +19 more
Jun 2, 2022
MDD Trial in United States (SP-624, Placebo)
Active, not recruiting
- Major Depressive Disorder
- SP-624
- Placebo
-
Phoenix, Arizona
- +38 more
May 13, 2022
MDD Trial in Worldwide (Lumateperone)
Enrolling by invitation
- Major Depressive Disorder
-
Phoenix, Arizona
- +44 more
Apr 7, 2022
MDD Trial in United States (BTRX-335140, Placebo)
Active, not recruiting
- Major Depressive Disorder
- BTRX-335140
- Placebo
-
Phoenix, Arizona
- +37 more
Mar 11, 2022
MDD Trial in United States (Levomilnacipran ER, Fluoxetine, Placebo)
Completed
- Major Depressive Disorder
- Levomilnacipran ER
- +2 more
-
Little Rock, Arkansas
- +50 more
Mar 1, 2022
Depression, MDD Trial in United States (AXS-05, Placebo)
Completed
- Depression
- Major Depressive Disorder
- AXS-05
- Placebo
-
Phoenix, Arizona
- +42 more
Sep 22, 2021
MDD Trial in United States (AXS-05, Bupropion)
Completed
- Major Depressive Disorder
-
Beverly Hills, California
- +3 more
Sep 22, 2021
MDD Trial in Worldwide (SPD489 (Lisdexamfetamine dimesylate) + Antidepressant)
Terminated
- Major Depressive Disorder
- SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
-
Birmingham, Alabama
- +211 more
Jun 9, 2021
MDD Trial in United States (Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + )
Completed
- Major Depressive Disorder
- Antidepressant + SPD489 (lisdexamfetamine dimesylate)
- Antidepressant + placebo
-
Newport Beach, California
- +14 more
Jun 8, 2021
MDD Trial in Worldwide (Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine
Completed
- Major Depressive Disorder
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
- +4 more
-
Little Rock, Arkansas
- +81 more
May 25, 2021
MDD Trial in United States (BTRX-246040 oral capsule(s), Placebo oral capsule(s))
Completed
- Major Depressive Disorder
- BTRX-246040 oral capsule(s)
- Placebo oral capsule(s)
-
Cerritos, California
- +7 more
Apr 19, 2021
MDD Trial in United States (CP-601,927, Placebo)
MDD Trial in Australia, Puerto Rico, United States (ALKS 5461, ALKS 5461 Placebo)
Completed
- Major Depressive Disorder
- ALKS 5461
- ALKS 5461 Placebo
-
Tucson, Arizona
- +34 more
Mar 15, 2021